LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

Kodu・Aktsiate loetelu・Thermo Fisher Scientific Inc
Search

Thermo Fisher Scientific Inc

Suletud

SektorTervishoid

492.82 1.27

Tugev "osta" hinnang

Hinna uuendus 29. mai 2026, 19:59 UTC

OstaMüü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

491.57

Max

495.72

Põhinäitajad

By Trading Economics

Sissetulek

-314M

1.7B

Müük

-1.2B

11B

P/E

Sektori keskmine

24.631

50.102

Aktsiakasum

5.44

Dividenditootlus

0.39

Kasumimarginaal

15.048

Töötajad

125,000

EBITDA

-905M

2.3B

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+25.87% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

0.39%

2.33%

Järgmine tulemuste avaldamine

22. juuli 2026

Järgmine dividendimakse kuupäev

15. juuli 2026

Järgmine aktsia dividendi kuupäev (ex-date)

15. juuni 2026

Turustatistika

By TradingEconomics

Turukapital

-29B

167B

Eelmine avamishind

491.55

Eelmine sulgemishind

492.82

Uudiste sentiment

By Acuity

35%

65%

96 / 344 Pingereas Healthcare

Thermo Fisher Scientific Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

23. apr 2026, 13:56 UTC

Tulu

Thermo Fisher Profit Up, Warns of Inflation from Iran War -- Update

DJ

Loe

23. apr 2026, 10:28 UTC

Tulu

Thermo Fisher Posts Higher 1Q Profit, Revenue

DJ

Loe

29. jaan 2026, 11:34 UTC

Tulu

Thermo Fisher 4Q Profit Rises as Biopharma Spending Rebounds

DJ

Loe

29. okt 2025, 10:51 UTC

Omandamised, ülevõtmised, äriostud

Thermo Fisher Scientific Agrees to Buy Clario Holdings for $8.88 billion

DJ

Loe

23. okt 2025, 20:49 UTC

Tulu

Correction to Thermo Fisher Article on Oct. 22

DJ

Loe

22. okt 2025, 10:28 UTC

Tulu

Thermo Fisher 3Q Revenue Rises, Boosted by Life Sciences Business

DJ

Loe

15. mai 2026, 10:45 UTC

Market Talk

Contract Drug Manufacturers to Benefit From U.S. Pharma Onshoring Push -- Market Talk

DJ

Loe

23. apr 2026, 10:01 UTC

Tulu

Thermo Fisher 1Q Organic Revenue Rose 1% >TMO

DJ

Loe

23. apr 2026, 10:01 UTC

Tulu

Thermo Fisher: Well Positioned to Deliver Strong Year >TMO

DJ

Loe

23. apr 2026, 10:00 UTC

Tulu

Thermo Fisher 1Q Net $1.65B >TMO

DJ

Loe

23. apr 2026, 10:00 UTC

Tulu

Thermo Fisher 1Q Adj EPS $5.44 >TMO

DJ

Loe

23. apr 2026, 10:00 UTC

Tulu

Thermo Fisher 1Q EPS $4.43 >TMO

DJ

Loe

23. apr 2026, 10:00 UTC

Tulu

Thermo Fisher 1Q Rev $11.01B >TMO

DJ

Loe

24. märts 2026, 12:04 UTC

Omandamised, ülevõtmised, äriostud

Thermo Fisher Completes Acquisition of Clario Holdings for $8.875 Billion >TMO

DJ

Loe

24. märts 2026, 12:00 UTC

Omandamised, ülevõtmised, äriostud

Thermo Fisher Scientific Completes Acquisition Of Clario Holdings, Inc. >TMO

DJ

Loe

29. jaan 2026, 11:01 UTC

Tulu

Thermo Fisher 4Q Organic Revenue Rose 3% >TMO

DJ

Loe

29. jaan 2026, 11:00 UTC

Tulu

Thermo Fisher: Entering 2026 From Position of Strength >TMO

DJ

Loe

29. jaan 2026, 11:00 UTC

Tulu

Thermo Fisher 4Q Net $1.96B >TMO

DJ

Loe

29. jaan 2026, 11:00 UTC

Tulu

Thermo Fisher 4Q Rev $12.22B >TMO

DJ

Loe

29. jaan 2026, 11:00 UTC

Tulu

Thermo Fisher 4Q EPS $5.21 >TMO

DJ

Loe

29. jaan 2026, 11:00 UTC

Tulu

Thermo Fisher 4Q Adj EPS $6.57 >TMO

DJ

Loe

29. okt 2025, 10:06 UTC

Omandamised, ülevõtmised, äriostud

Thermo Fisher: Clario Provides Endpoint Data Solutions for Clinical Trials >TMO

DJ

Loe

29. okt 2025, 10:05 UTC

Omandamised, ülevõtmised, äriostud

Thermo Fisher: Claro Deal Includes Potential Additional Earnout, Other Payments >TMO

DJ

Loe

29. okt 2025, 10:05 UTC

Omandamised, ülevõtmised, äriostud

Thermo Fisher to Buy Clario From Group Led by Astorg and Nordic Cap, Novo Holding, Cinven >TMO

DJ

Loe

29. okt 2025, 10:04 UTC

Omandamised, ülevõtmised, äriostud

Thermo Fisher Scientific to Pay $8.875 Billion at Closing for Clario Holdings >TMO

DJ

Loe

29. okt 2025, 10:00 UTC

Omandamised, ülevõtmised, äriostud

Thermo Fisher Scientific to Acquire Clario Holdings >TMO

DJ

Loe

22. okt 2025, 10:01 UTC

Tulu

Thermo Fisher 3Q Organic Revenue Rose 3% >TMO

DJ

Loe

22. okt 2025, 10:00 UTC

Tulu

Thermo Fisher: In Great Position to Deliver on 2025 Objectives >TMO

DJ

Loe

22. okt 2025, 10:00 UTC

Tulu

Thermo Fisher 3Q Adj EPS $5.79 >TMO

DJ

Loe

22. okt 2025, 10:00 UTC

Tulu

Thermo Fisher 3Q Rev $11.12B >TMO

DJ

Loe

Võrdlus sarnastega

Hinnamuutus

Thermo Fisher Scientific Inc Prognoos

Hinnasiht

By TipRanks

25.87% tõus

12 kuu keskmine prognoos

Keskmine 613.27 USD  25.87%

Kõrge 685 USD

Madal 490 USD

Põhineb 18 Wall Streeti analüütiku instrumendi Thermo Fisher Scientific Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

18 ratings

16

Osta

2

Hoia

0

Müü

Põhineb 18 analüütiku instrumendi Thermo Fisher Scientific Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

96 / 344 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Thermo Fisher Scientific Inc

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. It has a collaboration agreement with Mainz Biomed N.V. for the development of colorectal cancer screening product. Thermo Fisher Scientific Inc. was founded in 1956 and is headquar

Muud aktsiad sektorist

LLY

Eli Lilly and Co.

1,103

↓-2.23%

JNJ

Johnson and Johnson

225.18

↓-2.6%

ABBV

AbbVie Inc

217.96

↓-0.27%

UNH

UnitedHealth Group Inc

378.65

↓-0.98%

MRK

Merck & Co Inc.

118.6

↓-1.13%
help-icon Live chat